Sanofi Looks To BEYOND To Win China Diabetes Battle
This article was originally published in PharmAsia News
Executive Summary
As Sanofi enters a new phase in the insulin race amid heating competition in the country with the highest number of diabetics, it has outlined a new strategy in China, starting from a better understanding of the disease. It is also shifting from simply offering products to providing broader solutions, the firm’s global diabetes head Pierre Chancel says in an interview.